Zevra Therapeutics, Inc.
ZVRA
$8.33
-$0.06-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 98.36% | 474.94% | 81.36% | -79.67% | -220.49% |
| Total Depreciation and Amortization | -75.76% | 5.70% | 5.57% | 109.40% | 2,508.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.55% | -10,571.18% | 107.52% | 312.79% | 758.94% |
| Change in Net Operating Assets | -874.06% | -406.18% | -4,524.32% | -89.41% | -103.08% |
| Cash from Operations | 125.96% | 81.16% | 49.14% | -0.57% | -291.98% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 85.29% | 9,516.28% | -28.07% | -113.33% | 29.20% |
| Cash from Investing | 85.41% | 9,351.16% | -28.74% | -151.69% | 29.47% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | 100.00% | -- | 100.00% | -100.00% |
| Issuance of Common Stock | -89.92% | 187.71% | 62.61% | -86.96% | 122,098.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.92% | -90.99% | 32.05% | -84.09% | 146.64% |
| Foreign Exchange rate Adjustments | 113.03% | 106.27% | -726.67% | 92.26% | -381.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.48% | 388.99% | 1,877.50% | -9,106.36% | 164.46% |